Magrolimab plus azacitidine results in promising activity in higher-risk MDS patients

Myelodysplastic syndromes (MDS) are a diverse group of bone marrow disorders in which immature stem cells do not mature to become red blood cells, white blood cells or platelets. Patients with higher-risk MDS tend to have poorer outcomes, a greater chance of developing acute myeloid leukemia and few effective treatment options.

Leave A Comment

Your email address will not be published. Required fields are marked *